GeoVax Labs, Inc. 8-K

What Happened

• GeoVax Labs, Inc. announced on March 31, 2026 that it entered into inducement letters with holders of existing warrants to cash-exercise a total of 634,658 warrants at a reduced price of $1.36 per share, generating expected gross proceeds of approximately $863,000 (before fees and expenses). In exchange, GeoVax will issue new warrants to purchase up to 1,269,316 shares at the same $1.36 exercise price; the new warrants will expire five years after issuance and are substantially identical to the existing warrants. The company expects the closing to occur on April 1, 2026, subject to customary conditions.

Key Details

• Existing warrants being exercised total 634,658 shares; aggregate gross proceeds expected ≈ $863,000.
• New warrants cover up to 1,269,316 shares at $1.36 per share; exercisable after any required Nasdaq/stockholder approvals and expire five years from issuance.
• GeoVax engaged A.G.P./Alliance Global Partners as exclusive financial advisor, agreed to pay a cash fee equal to 7.0% of the gross proceeds to Dawson and to reimburse AGP up to $40,000 in legal expenses.
• Company will file a resale registration statement for the New Warrant Shares within 20 days of closing and agreed to hold a stockholder meeting on or before May 21, 2026 to obtain required approval.

Why It Matters

• This transaction provides near-term cash (about $863K gross) to fund general corporate purposes.
• It also creates potential future dilution: the new warrants could convert into up to 1.27 million additional shares if exercised. Investors should watch the upcoming registration filing and the scheduled stockholder meeting (by May 21, 2026) for approval details and any impact on share count.